1. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
- Author
-
van de Loosdrecht, A. A., primary, Cremers, E. M. P., additional, Alhan, C., additional, Duetz, C., additional, in ’t Hout, F. E. M., additional, Visser-Wisselaar, H. A., additional, Chitu, D. A., additional, Verbrugge, A., additional, Cunha, S. M., additional, Ossenkoppele, G. J., additional, Janssen, J. J. W. M., additional, Klein, S. K., additional, Vellenga, E., additional, Huls, G. A., additional, Muus, P., additional, Langemeijer, S. M. C., additional, de Greef, G. E., additional, te Boekhorst, P. A. W., additional, Raaijmakers, M. H. G., additional, van Marwijk Kooy, M., additional, Legdeur, M. C., additional, Wegman, J. J., additional, Deenik, W., additional, de Weerdt, O., additional, van Maanen-Lamme, T. M., additional, Jobse, P., additional, van Kampen, R. J. W., additional, Beeker, A., additional, Wijermans, P. W., additional, Biemond, B. J., additional, Tanis, B. C., additional, van Esser, J. W. J., additional, Schaar, C. G., additional, Noordzij-Nooteboom, H. S., additional, Jacobs, E. M. G., additional, de Graaf, A. O., additional, Jongen-Lavrencic, M., additional, Stevens-Kroef, M. J. P. L., additional, Westers, T. M., additional, and Jansen, J. H., additional
- Published
- 2024
- Full Text
- View/download PDF